China Medical System (CHSYF) Holdings announced that on 28 July, the New Drug Application for improved new drug ZUNVEYL has been accepted by the National Medical Products Administration of China. The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHSYF:
- China Medical System’s Alzheimer’s Drug ZUNVYL Gains Approval in China
- China Medical System Holdings Secures Secondary Listing on Singapore Exchange
- China Medical System’s CMS-D001 Receives Approval for Atopic Dermatitis Trials
- China Medical System Holdings Plans Secondary Listing on Singapore Exchange
- China Medical System Holdings Announces Eligibility for Secondary Listing on Singapore Exchange